Latest News - Oklahoma Society of Clinical Oncology

New ASCO-COA Oncology Medical Home Standards Set High Bar, Offers Roadmap for Comprehensive High-Quality, Patient-Centered Cancer Care Delivery 

On July 13, the American Society of Clinical Oncology (ASCO) and the Community Oncology Alliance (COA) jointly released new Oncology Medical Home (OMH) standards to provide a comprehensive roadmap for oncology practices to deliver high-quality, evidence based cancer care. By releasing the new standards, ASCO and COA seek to achieve a broad consensus among all […]

Read More

Oncopeptides announces that PEPAXTO® is now included in the NCCN Clinical Practice Guidelines.

Melphalan Flufenamide (PEPAXTO®) is now included in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma Version 6.2021 – April 12, 2021 Category 2A1 Definitions for National Comprehensive Cancer Network® (NCCN®) Categories:   Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.   For more […]

Read More

Oncopeptides Offers Virtual Webcast: The African American Experience in Multiple Myeloma

Multiple Myeloma is the 2nd most common blood cancer (Cancer Facts & Figures 2020), accounting for about 1.8% of all cancers (SEER Cancer Stat Facts: Myeloma) and is the leading hematologic cancer in African Americans (Pierre and Williams. Clin J Oncol Nursing. 2020;24:439-443). An estimated 32,000 patients were diagnosed with multiple myeloma in the United States in […]

Read More

OSCO and ASCO Supported Co-Pay Accumulator Ban Bill Signed into Law

On April 19, Oklahoma Governor Kevin Stitt (R) signed co-pay accumulator ban bill HB 2678 into law. This measure requires Pharmacy Benefit Managers (PBMs) to include any amount paid by an enrollee, or on behalf of an enrollee, when calculating the enrollee’s out of pocket maximum, copay, coinsurance, deductible, or cost sharing requirement. The Oklahoma […]

Read More

Natera announces allocation of $1,000,000 to Signatera Research Fund for initiatives that focus on using Signatera to develop or refine specific and defined medical knowledge.

Signatera Research Fund Natera supports independent research and education initiatives from the global healthcare community that align with Natera’s medical and scientific strategy for improving patient outcomes in areas of unmet medical need. This year, Natera has allocated $1,000,000 for research initiatives that are focused on using Signatera to develop or refine specific and defined […]

Read More

FDA approves KEYTRUDA® (pembrolizumab) for additional treatment.

Merck has announced that the FDA has approved KEYTRUDA® (pembrolizumab) for the treatment of patients with locally advanced or metastatic esophageal or gastroesophageal junction (GEJ) (tumors with epicenter 1 to 5 centimeters above the GEJ) carcinoma that is not amenable to surgical resection or definitive chemoradiation in combination with platinum- and fluoropyrimidine-based chemotherapy. PD-L1 diagnostic testing is […]

Read More

Oncopeptides offers new FDA Approved Treatment Option for Some Patients with Triple-Class Refractory Multiple Myeloma

Oncopeptides will host a seminar to explore a new therapy for adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy and whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one CD38-directed monoclonal antibody. Join OncLive® and Oncopeptides, along with experts […]

Read More

USDA Approves Bristol Myers Squibb’s and bluebird bio’s Abecma (idecabtagene vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed or Refractory Multiple Myeloma

Bristol Myers Squibb (NYSE: BMY) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that the U.S. Food and Drug Administration (FDA) has approved Abecma (idecabtagene vicleucel; ide-cel) as the first B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines […]

Read More

FDA approves Bristol Myers Squibb’s Onureg® (azacitidine tablets) for Continued Treatment of Acute Myeloid Leukemia

Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved Onureg® (azacitidine 300 mg tablets, CC-486) for the continued treatment of adult patients with acute myeloid leukemia (AML) who achieved first complete remission (CR) or CR with incomplete blood count recovery (CRi) following intensive induction chemotherapy and who are not able […]

Read More

Bristol Myers Squibb’s Breyanzi approved by FDA

Bristol Myers Squibb today announced that the U.S. Food and Drug Administration (FDA) has approved Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not […]

Read More